The tweet was deleted by the author.
But we saved everything 🙂.
The U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of McCune-Albright Syndrome, representing a significant regulatory milestone for Atossa Therapeutics.
Atossa Therapeutics said (Z)-endoxifen may address key drivers of the disease and improve patient outcomes. This move highlights the company's ongoing commitment to developing targeted therapies for rare conditions. The designation may provide additional incentives, including a potential priority review voucher if the therapy is approved.
Atossa Therapeutics has previously advanced Z-endoxifen in oncology, reporting key FDA designations and new clinical leadership earlier this year. The company has also explored endoxifen as a novel approach to managing Duchenne muscular dystrophy through recent presentations. These developments support Atossa's focus on expanding the potential uses of its pipeline therapies.